IMC Chicago’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.61M Buy
11,800
+3,400
+40% +$418K ﹤0.01% 3295
2026
Q1
$990K Buy
+8,400
New +$1.17M ﹤0.01% 3295
2025
Q4
Sell
-22,000
Closed -$2.94M 4373
2025
Q3
$2.94M Buy
+22,000
New +$2.67M ﹤0.01% 1979
2025
Q2
Sell
-17,300
Closed -$2.2M 3539
2025
Q1
$2.2M Sell
17,300
-2,200
-11% -$339K ﹤0.01% 1740
2024
Q4
$2.81M Sell
19,500
-2,100
-10% -$301K ﹤0.01% 1618
2024
Q3
$3.21M Sell
21,600
-7,700
-26% -$1.1M ﹤0.01% 1373
2024
Q2
$3.69M Buy
29,300
+17,500
+148% +$2.74M ﹤0.01% 1207
2024
Q1
$2.17M Buy
+11,800
New +$2.25M ﹤0.01% 1319

Other funds holding RGEN

IMC Chicago's RGEN Position: Q2 2026 in Review

IMC Chicago sold out of Repligen (RGEN) in Q2 2026, closing a stake of 9,012 shares — an estimated $1.11M sold.

IMC Chicago first reported a position in RGEN in Q1 2026 and held it in 1 quarter. The position peaked at $1.06M in Q1 2026. 482 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

  • IMC Chicago reported no remaining Repligen position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 9,012 Repligen shares in Q2 2026, an estimated $1.11M.
  • IMC Chicago first reported a position in Repligen in Q1 2026 and held it in 1 quarter.
  • IMC Chicago's Repligen position peaked at $1.06M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.